1-2 of 2
Gal Hacohen-Kleiman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial

Clinical Trials & Observations
Amitkumar Mehta, Leslie Popplewell, Graham P. Collins, Sonali M. Smith, Ian W. Flinn, Nancy L. Bartlett, Nilanjan Ghosh, Gal Hacohen-Kleiman, Yanan Huo, Linda Su-Feher, Camille Renard, Ranjana Advani, Mark Roschewski
Journal: Blood Advances
Blood Adv (2024) 8 (22): 5855–5863.
https://doi.org/10.1182/bloodadvances.2024013277
Published: 2024
Includes: Supplemental data
Journal Articles

Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Joseph E. Maakaron, Adam Asch, Leslie Popplewell, Graham P. Collins, Ian W. Flinn, Nilanjan Ghosh, Colm Keane, Matthew Ku, Amitkumar Mehta, Mark Roschewski, Gal Hacohen-Kleiman, Yanan Huo, Yi Zhang, Camille Renard, Sonali M. Smith, Ranjana Advani
Journal: Blood Advances
Blood Adv (2024) 8 (22): 5864–5874.
https://doi.org/10.1182/bloodadvances.2024013338
Published: 2024
Includes: Supplemental data